Clinical Trial Update: Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cediranib plus olaparib in recurrent platinum-resistant ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Recurrent Platinum Resistant Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-08-20